Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response
Authors:
- Laura Martín de la FuenteLFLaura Martín de la Fuente
- Susanne MalanderSMSusanne Malander
- Linda HartmanLHLinda Hartman
- Jenny-Maria JönssonJJJenny-Maria Jönsson
- Anna EbbessonAEAnna Ebbesson
- Mef NilbertMNMef Nilbert
- Anna MåsbäckAMAnna Måsbäck
- Ingrid HedenfalkIHIngrid Hedenfalk
Open Access
- 1 March 2018
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 37 (2) , 101-109
Abstract
The tight junction protein claudin-4 has been reported to be overexpressed in advanced ovarian cancer. We investigated the prognostic significance of claudin-4 overexpression and whether claudin-4 expression could predict platinum response in primary ovarian carcinoma (OC). Claudin-4 expression was evaluated by immunohistochemistry in a tissue microarray of 140 OCs. Multivariable Cox-regression models were used to assess the effect of claudin-4 overexpression on progression-free survival and overall survival (OS). Kaplan-Meier survival analyses and the logrank test were performed comparing claudin-4 high and low groups. The association between claudin-4 expression and platinum resistance was assessed using risk ratios and the Pearson χ2 test. A dataset of >1500 epithelial ovarian cancers was used to study the association between CLDN4 mRNA and survival. Of 140 evaluable cases, 71 (51%) displayed high claudin-4 expression. Claudin-4 overexpression predicted shorter 5-yr progression-free survival and OS in univariable analyses [hazard ratio (HR)=1.6 (1.1–2.5), P=0.020 and HR=1.6 (1.0–2.4), P=0.041, respectively]. Hazard of relapse was similar [HR=1.5 (1.0–2.4)] after adjustment for age, stage, type, and BRCA1/2 status in a multivariable analysis, but the evidence was slightly weaker (P=0.076). Validation in an external cohort confirmed the association between high expression of CLDN4 and poor 10-yr OS [HR=1.3 (1.1–1.5), PP=0.3]. These findings suggest that high expression of claudin-4 may have a prognostic value in OC. The role of claudin-4 in the development of platinum resistance remains unclear.Keywords
This publication has 46 references indexed in Scilit:
- Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental PlatformsFrontiers in Oncology, 2013
- Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patientsEndocrine-Related Cancer, 2012
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying TheoryAmerican Journal of Surgical Pathology, 2010
- Carcinoma of the OvaryInternational Journal of Gynecology & Obstetrics, 2006
- Proteins Associated with Cisplatin Resistance in Ovarian Cancer Cells Identified by Quantitative Proteomic Technology and Integrated with mRNA Expression LevelsMolecular & Cellular Proteomics, 2006
- Claudins upregulation in human colorectal cancerFEBS Letters, 2005
- Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial DesignJournal of Clinical Oncology, 2004
- The tight junction: a multifunctional complexAmerican Journal of Physiology-Cell Physiology, 2004
- Claudin 4 Protein Expression in Primary and Metastatic Pancreatic Cancer Support for Use as a Therapeutic TargetAmerican Journal of Clinical Pathology, 2004
- Drug resistance in ovarian cancer: from the laboratory to the clinicObstetrics & Gynecology, 1998